BlackRock Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlackRock Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$9.49M	Sell	134,979 -18,420	-12%	-$1.31M	0.01%	1147
2016 Q3	$10.9M	Buy	153,399 +846	+0.6%	+$54K	0.01%	951
2016 Q2	$7.46M	Buy	152,553 +1,640	+1%	+$106K	0.01%	1147
2016 Q1	$9.55M	Sell	150,913 -16,956	-10%	-$1.11M	0.01%	953
2015 Q4	$18.8M	Buy	167,869 +1,140	+0.7%	+$114K	0.02%	604
2015 Q3	$16.1M	Buy	166,729 +18,200	+12%	+$2.08M	0.02%	652
2015 Q2	$15.2M	Buy	148,529 +99,271	+202%	+$7.71M	0.02%	724
2015 Q1	$3.06M	Buy	49,258 +2,927	+6%	+$163K	﹤0.01%	1730
2014 Q4	$2.03M	Sell	46,331 -93	-0.2%	-$4.26K	﹤0.01%	2025
2014 Q3	$2.63M	Buy	46,424 +869	+2%	+$43.7K	﹤0.01%	1798
2014 Q2	$2.04M	Buy	45,555 +26,546	+140%	+$1.09M	﹤0.01%	2062
2014 Q1	$929K	Buy	+19,009	New	+$979K	﹤0.01%	2558

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock Investment Management's RARE Position: Q4 2016 in Review

BlackRock Investment Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 12% in Q4 2016, selling an estimated $1.31M and leaving 134,979 shares worth $9.49M. The position accounts for 0.01% of the portfolio, ranked #1147.

BlackRock Investment Management first reported a position in RARE in Q1 2014 and has held it in 12 quarters since. The position peaked at $18.8M in Q4 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

BlackRock Investment Management held 134,979 shares of Ultragenyx Pharmaceutical worth $9.49M as of Q4 2016.
BlackRock Investment Management sold 18,420 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $1.31M.
Ultragenyx Pharmaceutical made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1147 holding.
BlackRock Investment Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 12 quarters since.
BlackRock Investment Management's Ultragenyx Pharmaceutical position peaked at $18.8M in Q4 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.